Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Trial of Sodium Phenylbutyrate–Taurursodiol for Amyotrophic Lateral Sclerosis
Sabrina Paganoni, Eric A. Macklin, Suzanne Hendrix, et al.
New England Journal of Medicine (2020) Vol. 383, Iss. 10, pp. 919-930
Open Access | Times Cited: 443

Showing 1-25 of 443 citing articles:

Molecular mechanisms of cell death in neurological diseases
Diane Moujalled, Andreas Strasser, Jeffrey R. Liddell
Cell Death and Differentiation (2021) Vol. 28, Iss. 7, pp. 2029-2044
Open Access | Times Cited: 505
Oxidative Stress and Antioxidants in Neurodegenerative Disorders
Edward O. Olufunmilayo, Michelle B. Gerke-Duncan, R. M. Damian Holsinger
Antioxidants (2023) Vol. 12, Iss. 2, pp. 517-517
Open Access | Times Cited: 289
Recent developments of HDAC inhibitors: Emerging indications and novel molecules
Andrey D. Bondarev, Misty M. Attwood, Jörgen Jönsson, et al.
British Journal of Clinical Pharmacology (2021) Vol. 87, Iss. 12, pp. 4577-4597
Open Access | Times Cited: 286
Amyotrophic lateral sclerosis: a neurodegenerative disorder poised for successful therapeutic translation
Richard J. Mead, Ning Shan, H. Joseph Reiser, et al.
Nature Reviews Drug Discovery (2022) Vol. 22, Iss. 3, pp. 185-212
Open Access | Times Cited: 269
Microbiota–gut–brain axis and its therapeutic applications in neurodegenerative diseases
Jian Sheng Loh, Wen Qi Mak, Li Tan, et al.
Signal Transduction and Targeted Therapy (2024) Vol. 9, Iss. 1
Open Access | Times Cited: 255
Improving clinical trial outcomes in amyotrophic lateral sclerosis
Matthew C. Kiernan, Steve Vucic, Kevin Talbot, et al.
Nature Reviews Neurology (2020) Vol. 17, Iss. 2, pp. 104-118
Open Access | Times Cited: 231
Long‐term survival of participants in the CENTAUR trial of sodium phenylbutyrate‐taurursodiol in amyotrophic lateral sclerosis
Sabrina Paganoni, Suzanne Hendrix, Samuel P. Dickson, et al.
Muscle & Nerve (2020) Vol. 63, Iss. 1, pp. 31-39
Open Access | Times Cited: 149
Anti-Amyloid Monoclonal Antibodies are Transformative Treatments that Redefine Alzheimer's Disease Therapeutics
Jeffrey L. Cummings
Drugs (2023) Vol. 83, Iss. 7, pp. 569-576
Open Access | Times Cited: 146
iPSC-based disease modeling and drug discovery in cardinal neurodegenerative disorders
Hideyuki Okano, Satoru Morimoto
Cell stem cell (2022) Vol. 29, Iss. 2, pp. 189-208
Open Access | Times Cited: 122
“Sweet death”: Fructose as a metabolic toxin that targets the gut-liver axis
Mark A. Febbraio, Michael Karin
Cell Metabolism (2021) Vol. 33, Iss. 12, pp. 2316-2328
Open Access | Times Cited: 108
Genetics of amyotrophic lateral sclerosis: seeking therapeutic targets in the era of gene therapy
Naoki Suzuki, Ayumi Nishiyama, Hitoshi Warita, et al.
Journal of Human Genetics (2022) Vol. 68, Iss. 3, pp. 131-152
Open Access | Times Cited: 93
Tauroursodeoxycholic acid: a potential therapeutic tool in neurodegenerative diseases
Kareem Khalaf, Paolo Tornese, Antoniangela Cocco, et al.
Translational Neurodegeneration (2022) Vol. 11, Iss. 1
Open Access | Times Cited: 81
Current State and Future Directions in the Therapy of ALS
Laura Tzeplaeff, Sibylle Wilfling, Maria Viktoria Requardt, et al.
Cells (2023) Vol. 12, Iss. 11, pp. 1523-1523
Open Access | Times Cited: 59
Effects of tofersen treatment in patients with SOD1-ALS in a “real-world” setting – a 12-month multicenter cohort study from the German early access program
Maximilian Wiesenfarth, Johannes Dorst, Dávid Brenner, et al.
EClinicalMedicine (2024) Vol. 69, pp. 102495-102495
Open Access | Times Cited: 47
European Academy of Neurology (EAN) guideline on the management of amyotrophic lateral sclerosis in collaboration with European Reference Network for Neuromuscular Diseases (ERNEURO‐NMD)
Philip Van Damme, Ammar Al‐Chalabi, Peter M. Andersen, et al.
European Journal of Neurology (2024) Vol. 31, Iss. 6
Open Access | Times Cited: 40
The sense of antisense therapies in ALS
Sien Hilde Van Daele, Pegah Masrori, Philip Van Damme, et al.
Trends in Molecular Medicine (2024) Vol. 30, Iss. 3, pp. 252-262
Open Access | Times Cited: 24
TDP-43-stratified single-cell proteomics of postmortem human spinal motor neurons reveals protein dynamics in amyotrophic lateral sclerosis
Amanda J. Guise, Santosh A. Misal, Richard H. Carson, et al.
Cell Reports (2024) Vol. 43, Iss. 1, pp. 113636-113636
Open Access | Times Cited: 23
The bile acid TUDCA and neurodegenerative disorders: An overview
Lucas Zangerolamo, Jean Franciesco Vettorazzi, Lucas Rodolfo de Oliveira Rosa, et al.
Life Sciences (2021) Vol. 272, pp. 119252-119252
Closed Access | Times Cited: 94
Small molecule modulation of a redox-sensitive stress granule protein dissolves stress granules with beneficial outcomes for familial amyotrophic lateral sclerosis models
Hiroyuki Uechi, Sindhuja Sridharan, Jik Nijssen, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2019)
Open Access | Times Cited: 84
From dried bear bile to molecular investigation: A systematic review of the effect of bile acids on cell apoptosis, oxidative stress and inflammation in the brain, across pre-clinical models of neurological, neurodegenerative and neuropsychiatric disorders
Fei Huang, Carmine M. Pariante, Alessandra Borsini
Brain Behavior and Immunity (2021) Vol. 99, pp. 132-146
Closed Access | Times Cited: 78
Pharmacotherapy for Amyotrophic Lateral Sclerosis: A Review of Approved and Upcoming Agents
Stephen A. Johnson, Ton Fang, Fabiola De Marchi, et al.
Drugs (2022) Vol. 82, Iss. 13, pp. 1367-1388
Closed Access | Times Cited: 64
Multicentre appraisal of amyotrophic lateral sclerosis biofluid biomarkers shows primacy of blood neurofilament light chain
Alexander G. Thompson, Elizabeth Gray, Nick Verber, et al.
Brain Communications (2022) Vol. 4, Iss. 1
Open Access | Times Cited: 61
The Role of Mitochondrial Dysfunction and ER Stress in TDP-43 and C9ORF72 ALS
Ruxandra Dafinca, Paola Barbagallo, Kevin Talbot
Frontiers in Cellular Neuroscience (2021) Vol. 15
Open Access | Times Cited: 59
Role of Oxidative Stress in the Pathogenesis of Amyotrophic Lateral Sclerosis: Antioxidant Metalloenzymes and Therapeutic Strategies
Pavlína Hemerková, Martin Vališ
Biomolecules (2021) Vol. 11, Iss. 3, pp. 437-437
Open Access | Times Cited: 58
Effect of sodium phenylbutyrate/taurursodiol on tracheostomy/ventilation-free survival and hospitalisation in amyotrophic lateral sclerosis: long-term results from the CENTAUR trial
Sabrina Paganoni, Suzanne Hendrix, Samuel P. Dickson, et al.
Journal of Neurology Neurosurgery & Psychiatry (2022) Vol. 93, Iss. 8, pp. 871-875
Open Access | Times Cited: 58
Page 1 - Next Page

Scroll to top